Duloxetine HCl
| Nome del prodotto | Duloxetine HCl |
|---|---|
| Numero CAS | 136434-34-9 |
| Formula molecolare | C18H19NOS·HCl |
| Peso molecolare | 333.88 g/mol |
| Aspetto | Polvere cristallina di colore da bianco a bianco sporco |
| Analisi (HPLC) | 98.0% – 102.0% (on dried basis) |
| Perdita per essiccazione | ≤ 0,51 TP3T |
| Residuo di combustione | ≤ 0,11 TP3T |
| Metalli pesanti | ≤ 20 ppm |
| Confezione | 25 kg fiber drum with double polyethylene bags |
Hai bisogno di aiuto? Contatta il nostro team

Sinonimi: (S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine hydrochloride, LY248686, Duloxetine hydrochloride, Cymbalta, Yentreve, Ariclaim, Xeristar
Duloxetine HCl is a dual serotonin and norepinephrine reuptake inhibitor (SNRI) that has become a cornerstone in the treatment of major depressive disorder, generalized anxiety disorder, and neuropathic pain. As a hydrochloride salt, it offers improved aqueous solubility and stability compared to the free base, making it the preferred form for oral solid dosage formulations. The compound was originally developed by Eli Lilly and received FDA approval in 2004 under the brand name Cymbalta.
Chemically, duloxetine HCl is a naphthalenyloxy-substituted thiophene propanamine. Its structure features a chiral center, and the active pharmaceutical ingredient is the (S)-enantiomer, which is significantly more potent than the (R)-enantiomer. The molecule’s lipophilic naphthalene and thiophene rings facilitate blood-brain barrier penetration, while the secondary amine side chain is responsible for its interaction with serotonin and norepinephrine transporters. This dual mechanism distinguishes it from selective serotonin reuptake inhibitors (SSRIs) and contributes to its broader efficacy profile.
From a manufacturing perspective, duloxetine HCl is synthesized through a multi-step process that typically starts from 1-naphthol and 2-acetylthiophene, followed by a resolution step to isolate the desired (S)-enantiomer. The final hydrochloride salt is crystallized to high purity, with particle size distribution carefully controlled to ensure consistent dissolution and bioavailability in finished dosage forms. Our material is produced under cGMP conditions and is supported by a comprehensive regulatory package, including DMF and CEP where applicable.
| Parametro | Specifiche |
|---|---|
| Analisi (HPLC) | 98.0% – 102.0% |
| Identificazione | I tempi di ritenzione IR, UV e HPLC corrispondono allo standard di riferimento |
| Perdita per essiccazione | ≤ 0,51 TP3T |
| Residuo di combustione | ≤ 0,11 TP3T |
| Metalli pesanti | ≤ 20 ppm |
| Limiti microbiologici | Conta aerobica totale ≤ 1000 UFC/g; lieviti e muffe ≤ 100 UFC/g; assenza di E. coli |
Room,5-0203, Unit 5, Beiyuanmen Street,Xi'an,Shaanxi,China